TriSalus Life Sciences (TLSI) executive compensation, 2026 proxy

Mary Szela, CEO and President, was paid $4.8M in 2025, up 17% from $4.1M the year before.

Filed
March 31, 2026
Annual meeting
May 14, 2026
Pay year
2025
Named executives
3
CEO total pay
$4.8M+17% vs prior year
CEO pay in equity
84%$4.1M in awards
CEO 2025 Total Pay
$4,823,349Increase from prior year
CFO Signing Bonus
$159,000Paid upon joining July 1, 2025
Target Bonus Percentage
58%Attainment level for 2025

How Szela was paid

$4.8M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary12%Bonus3%Stock awards53%Option awards31%All other compensation0%

Named executive officers

ExecutiveTotal
Mary SzelaCEO and President$4,823,349
David PatienceChief Financial Officer$3,443,628
Richard MarshakChief Commercial Officer$1,556,000

What changed and why

  • $4.8MMary Szela received total compensation of $4,823,349 in 2025 compared to $4,136,595 in 2024.
  • Certain named executives participated in a salary investment program foregoing base salary for RSUs.
  • David Patience joined the company as Chief Financial Officer on July 1, 2025.
  • 58%Named executive officers were entitled to receive 58% of their target bonus for 2025.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.